ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc (ALNY)

235.53
-0.06
( -0.03% )
Updated: 13:39:51

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
235.53
Bid
235.43
Ask
236.03
Volume
347,926
231.01 Day's Range 238.53
141.975 52 Week Range 263.73
Market Cap
Previous Close
235.59
Open
236.12
Last Trade
1
@
235.73
Last Trade Time
13:39:51
Financial Volume
$ 81,969,609
VWAP
235.595
Average Volume (3m)
1,050,804
Shares Outstanding
126,491,778
Dividend Yield
-
PE Ratio
-67.72
Earnings Per Share (EPS)
-3.48
Revenue
1.83B
Net Profit
-440.24M

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari fo... Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Alnylam Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALNY. The last closing price for Alnylam Pharmaceuticals was $235.59. Over the last year, Alnylam Pharmaceuticals shares have traded in a share price range of $ 141.975 to $ 263.73.

Alnylam Pharmaceuticals currently has 126,491,778 shares outstanding. The market capitalization of Alnylam Pharmaceuticals is $29.80 billion. Alnylam Pharmaceuticals has a price to earnings ratio (PE ratio) of -67.72.

Alnylam Pharmaceuticals (ALNY) Options Flow Summary

Overall Flow

Bearish

Net Premium

-2k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

ALNY Latest News

Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday...

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

− Achieved 28% and 33% Reduction in Composite of All-Cause Mortality and Recurrent Cardiovascular Events in the Overall and Monotherapy Populations, Respectively – − Reduced All-Cause Mortality...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-22.47-8.70930232558258260.9231.01840563241.21628292CS
414.166.39653069522221.37263.73220.51454526246.44239302CS
1289.4661.2446087492146.07263.73143.671050804206.82480452CS
2650.7727.478891535184.76263.73141.975928731182.27259846CS
5233.7616.731922486201.77263.73141.975764359180.97909804CS
15653.5329.4120879121182263.73117.58786352184.21968924CS
260158.95207.56072081576.58263.7367.55730652163.84274605CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DCAPUnity Wealth Partners Dynamic Capital Appreciation & Options ETF
 20.10
(839.25%)
128.77k
RGCRegencell Bioscience Holdings Ltd
$ 29.60
(778.34%)
473.64k
SLRXSalarius Pharmaceuticals Inc
$ 3.96
(157.14%)
53.96M
ATPCAgape ATP Corporation
$ 0.2274
(59.02%)
96.67M
SPWRSunPower Corporation
$ 1.085
(51.58%)
148.42M
FLYEFly E Group Inc
$ 1.3701
(-78.53%)
12.92M
RNAZTransCode Therapeutics Inc
$ 0.30
(-62.15%)
7.76M
JAGXJaguar Health Inc
$ 1.8501
(-56.67%)
13.82M
MIRAMIRA Pharmaceuticals Inc
$ 2.43
(-51.50%)
23.1M
CMAXCareMax Inc
$ 3.48
(-32.95%)
7.61M
ADILAdial Pharmaceuticals Inc
$ 1.43
(34.91%)
154.62M
SPWRSunPower Corporation
$ 1.085
(51.58%)
148.42M
SLNASelina Hospitality PLC
$ 0.025
(-32.43%)
118.75M
NVDANVIDIA Corporation
$ 122.70
(-0.68%)
113.85M
ATPCAgape ATP Corporation
$ 0.2274
(59.02%)
96.67M

ALNY Discussion

View Posts
whytestocks whytestocks 4 years ago
Just In: $ALNY Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?

In 1962, the Nobel Prize was awarded to Francis Crick and James Watson for their discoveries related to deoxyribonucleic acid (DNA), the genetic code that provides instructions to cells. Messenger ribonucleic acid (mRNA), the intermediate step between DNA and proteins, can be bound and degr...

Got this from ALNY - Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?
👍️0
MinnieM MinnieM 4 years ago
Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19

https://investors.alnylam.com/press-release?id=24796

May 04, 2020

- Highly Potent and Broadly Cross-Reactive RNAi Therapeutic Development Candidate Selected Only Three Months After Program Initiation -

- Companies Expect to Start Human Clinical Trials at or Around Year-End 2020 –








👍️0
whytestocks whytestocks 5 years ago
$ALNY short squeeze article Alnylam Pharmaceuticals Inc Nasdaq Alny Short Squeeze
👍️0
whytestocks whytestocks 5 years ago
News: $ALNY Alnylam to Webcast Presentations at Upcoming December Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Evercore ISI 2 nd Annual HealthCONx Conference on Wednesday, December 4, 2019 at 1:15 pm ET at the Four Se...

Got this from ALNY - Alnylam to Webcast Presentations at Upcoming December Investor Conferences
👍️0
zerowinner zerowinner 5 years ago
Stock is going to the moon
👍️0
whytestocks whytestocks 5 years ago
News: $ALNY Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI(TM) (givosiran)

− Framework Ties Payment for GIVLAARI to its Delivery of Patient Outcomes in the Real-World Setting - − Includes New Approach Designed for Ultra-Rare Diseases that Gives Participating Payers Greater Financial Certainty if Disease Prevalence is Higher Than Anticipated ...

Read the whole news ALNY - Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI(TM) (givosiran)
👍️0
whytestocks whytestocks 5 years ago
News: $ALNY Alnylam Announces Approval of GIVLAARI(TM) (givosiran) by the U.S. Food and Drug Administration (FDA)

− GIVLAARI Approved for the Treatment of Adults with Acute Hepatic Porphyria (AHP) Based on ENVISION Phase 3 Study Results Showing Significant Reduction in the Rate of Porphyria Attacks in Patients with AHP – − FDA Approval Received in Less Than Four Months after N...

Read the whole news ALNY - Alnylam Announces Approval of GIVLAARI(TM) (givosiran) by the U.S. Food and Drug Administration (FDA)
👍️0
whytestocks whytestocks 5 years ago
News: $ALNY Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

− Initial Results From ILLUMINATE-C Expected in Late 2020 – − In Phase 2 OLE, Lumasiran Treatment Resulted in 76 percent Mean Maximal Reduction in Urinary Oxalate Relative to Phase 1/2 Baseline – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leadi...

Got this from ALNY - Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
👍️0
Glider549 Glider549 5 years ago
Phase 3 data, due in the 3rd quarter of 2019.
👍️0
MinnieM MinnieM 6 years ago
It's going a bit crazy in the after hours market.






👍️0
doughboy2 doughboy2 6 years ago
Agree.
👍️0
MinnieM MinnieM 6 years ago
It will be interesting to see the following weeks prices.






👍️0
oxnous oxnous 6 years ago
Who would have predicted that ALNY would get to this price without significant revenues yet?
👍️0
FooBarAndGrill FooBarAndGrill 7 years ago
IMO of course.

Recent Statement of Changes in Beneficial Ownership.

On November 15 2017 John Marangamore, Chief Executive Officer, in my opinion Acquired 74000 shares at $31.39 and Disposed 74000 at $126.864 for a computed amount of $9,387,951.301


W O R K S H E E T

22460 * $125.544 = 2819718.24
28399 * $126.603 = 3595398.597
07120 * $127.540 = 0908084.80
10571 * $128.484 = 1358204.364
04850 * $129.570 = 0628414.5
00600 * $130.218 = 0078130.8
------------------------------------
74000 * $126.864 = 9387951.301

Compare these computed numbers to other numbers in the most recent 10-q and draw your own conclusions.

IMO of course.
👍️0
FooBarAndGrill FooBarAndGrill 7 years ago
IMO of course.

Summary of recent Statement of Changes in Beneficial Ownership.

On September 20 2017 Barry E Greene, President, in my opinion Acquired 76815 shares at $31.39 and Disposed 76815 at $100 for a computed amount of $5,270,277.15

On October 2 2017 Barry E Greene, President, in my opinion Acquired 85316 shares at $21.35 and Disposed 85316 at $125 for a computed amount of $8,843,003.40

Barry E Greene, President has thus in my opinion realized a computed total gain of $14,113,280.55 from the option exercises noted above.

Compare these computed numbers to other numbers in the most recent 10-q and draw your own conclusions.

IMO of course.
👍️0
FooBarAndGrill FooBarAndGrill 7 years ago
About RNAi

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding protein synthesis in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, with the goal of preventing disease-causing proteins from being made.
👍️0
BottomBounce BottomBounce 7 years ago
$ALNY Alnylam Pharmaceuticals Inc. https://www.barchart.com/story/stocks/quotes/OTIC/news/3925902/best-relative-performance-in-the-biotechnology-industry-detected-in-shares-of-coherus-bioscien-chrs-otic-tsro-imgn-alny
👍️0
FooBarAndGrill FooBarAndGrill 7 years ago
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 2 clinical study with cemdisiran (formerly known as ALN-CC5), a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases. The trial is being conducted in patients with atypical hemolytic-uremic syndrome (aHUS) and will evaluate the effect of C5 knockdown on hematologic response and renal function, as well as safety and tolerability. The Company expects to report initial clinical proof of concept data from this trial in late 2018.
👍️0
FooBarAndGrill FooBarAndGrill 7 years ago
I've been following developments in RNAI for years. It's great to finally see progress in this powerful tech.
👍️0
Inoviorulez Inoviorulez 7 years ago
https://seekingalpha.com/article/4109199-alnylam-sanofi-achieve-rnai-first
👍️0
FooBarAndGrill FooBarAndGrill 7 years ago
In addition to new data on the Company’s ESC+ platform, Alnylam scientists and collaborators presented additional pre-clinical findings showing continued leadership in RNAi technologies and delivery. First, Alnylam scientists presented further advances toward optimizing the Company’s GalNAc-siRNA conjugate platform. These included studies to further improve the mechanistic understanding of conjugate duration of activity as well as the development of advanced ESC designs with significantly improved metabolic stability and in vivo efficacy. Further, new data on Alnylam’s Reversir™ platform were presented. Specifically, optimizations were implemented that enable rapid reversal of siRNA-mediated mRNA silencing, providing the means to fine-tune the pharmacology of GalNAc-siRNA conjugates. Finally, pre-clinical data demonstrating extra-hepatic siRNA delivery, involving Centyrins, a novel class of highly stable FN3 domain proteins, were also presented as part of a research collaboration with Janssen Research & Development, LLC. Centyrin-siRNA conjugates showed excellent cross-tumor penetration and mediated robust target knockdown in a mouse xenograft tumor model. Also, the generalizability of this approach was demonstrated in vitro using Centyrins for a number of different receptors and gene targets.
👍️0
FooBarAndGrill FooBarAndGrill 7 years ago
“At Alnylam, we’ve been successful in advancing our ESC GalNAc-siRNA conjugate platform with many potent and generally well tolerated investigational RNAi therapeutics in clinical development, including in Phase 3 studies. Nevertheless, we continue to strive to even further optimize our RNAi therapeutics platform to achieve improved target specificity and an even greater therapeutic index. Accordingly, we were pleased to share these new pre-clinical results at this year's OTS meeting, highlighting our ESC+ GalNAc conjugate platform,” said Kevin Fitzgerald, Ph.D., Senior Vice President, Research at Alnylam. “Our goal is to employ the ESC+ chemistry in all future development candidates, beginning with ALN-AAT02, which we plan to advance into clinical development in 2018. We believe that by implementing platform improvements that preemptively address potential off-target effects we can further enhance the therapeutic index of our investigational RNAi therapeutics for all future programs in our pipeline.”
👍️0
FooBarAndGrill FooBarAndGrill 7 years ago
ESC+ GalNAc conjugates utilize advanced design features to further improve specificity, including a glycol nucleic acid (GNA) modification in the antisense seed region of the siRNA, while maintaining potency and durability. The data presented at OTS indicated that incorporation of GNA destabilizes seed-driven pairing with partially complementary transcripts, thus greatly reducing potential off-target effects while maintaining on-target pairing and activity. Additionally, it was shown that GNA modifications confer enhanced specificity and a greater-than 6-fold improvement in therapeutic index as observed in pre-clinical studies in rodents. The ESC+ design is now being applied to all of Alnylam’s pre-clinical programs and has shown successful translation of potency from rodents to non-human primates. Alnylam intends to employ its ESC+ siRNA-conjugate platform in all future development programs.
👍️0
FooBarAndGrill FooBarAndGrill 7 years ago
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the Company presented new pre-clinical data highlighting its next generation “Enhanced Stabilization Chemistry Plus” (ESC+) GalNAc-siRNA conjugate platform at the 13th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held September 24 – 27, 2017 in Bordeaux, France.

👍️0
FooBarAndGrill FooBarAndGrill 7 years ago
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares jumped more than 40% on Wednesday after the pharma company, together with Sanofi Genzyme, the specialty care global business unit of Sanofi, announced that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic designed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint and all secondary endpoints. "We are very proud to report the first ever positive Phase 3 results for an RNAi therapeutic, marking the potential arrival of an entirely new class of medicines. This moment is the culmination of a 15-year journey of tireless work by countless contributors who have overcome enormous scientific and business challenges to make RNAi therapeutics a reality," said John Maraganore, Ph.D., Chief Executive Officer of Alnylam.
👍️0
NewTrader93 NewTrader93 7 years ago
I am a finance graduate and have always been interested in trading but have never truly started researching until now. after looking at what has happened with this company and its stock price. such a spike would potentially lead to just as dramatic a drop in price, thus giving way to a great opportunity to short which you have stated correct?
👍️0
Bernstein Bernstein 7 years ago
FANTASTIC SHORT OPP TODAY...

$10 BILLION UNPROFITABLE BUBBLE FRAUD WHICH BURNING $120+ MILLION A QUARTER AN HAVE $200 MILLION DEBT = BRUTAL PONZI SCEHEME FRAUD ONGOING HERE TO ATTRACT NEWBIES SO THE CRIMINAL BANKSTERS AND BOARD MEMEBRS CAN UNLOAD THEIR TRASH = NEXT MEGA SCAM LIKE VALEANT VRX = FAIR VALUE $10 AT BEST
👍️0
Inoviorulez Inoviorulez 7 years ago
https://seekingalpha.com/article/4101274-alnylam-q3-catalysts-play
👍️0
Inoviorulez Inoviorulez 7 years ago
https://seekingalpha.com/article/4086761-alnylam-sanofi-produce-monster-alternative-hemophilia-market
👍️0
stocktrademan stocktrademan 7 years ago
ALNY buy option 71.49

buy 16 JUN 17 75 call for 2.40









normal chart




log chart



👍️0
PennyStockC PennyStockC 8 years ago
Back over 40/share by Tuesday.

Anyone ready?!
👍️0
rivervalley rivervalley 8 years ago
Liking it putting in a new high since earlier. Keep rolling on up ALNY.
👍️0
PennyStockC PennyStockC 8 years ago
Back to over 38 we go today alone.

Weeeee
👍️0
rivervalley rivervalley 8 years ago
So far hod 36.07, keep it rolling :)
👍️0
rivervalley rivervalley 8 years ago
Picked up a starter in pm.
👍️0
PennyStockC PennyStockC 8 years ago
After hours news prompting investigation... Ffs,
I'm flipping hard. GAP UP in am???
👍️0
ClarkKant ClarkKant 8 years ago
Buyers stepping up now $35.90 after the two hour short pullback. If they cover tomorrow....easy $40+
👍️0
ClarkKant ClarkKant 8 years ago
Shorts are in control right now $36.70. Looks like it is heading for a new LOD unless some covering takes place before EOD.
👍️0
conix conix 8 years ago
ALNY? Bouncer?

👍️0
ClarkKant ClarkKant 8 years ago
Too many shorts now @ $37.50. Will have a hard time getting to $40 or any big move up today unless those $35 and $36 shorts cover.

GLTY
👍️0
ClarkKant ClarkKant 8 years ago
$36.50 was strong support on the pullback from $37.40 bounce but needs to break $37.50 for the next leg if it's going to recover some more.
👍️0
ClarkKant ClarkKant 8 years ago
$35.80 i want to see $40+!
👍️0
T695 T695 8 years ago
Watching for a bounce
👍️0
JTrader JTrader 8 years ago
Oversold. I'll be waiting at the bottom either tomorrow or Friday. They have too much in the pipeline and too many products already out there.
👍️0
venturecapp venturecapp 8 years ago
lnylam Pharmaceuticals Is About to Compete With One of the Worlds Most Expensive Drugs

http://marketexclusive.com/alnylam-pharmaceuticals-inc-nasdaqalny-compete-one-worlds-expensive-drugs/6265/?icd1
👍️0
2H2 2H2 8 years ago
Daily bull flag breakout.

HH
👍️0
stocktrademan stocktrademan 9 years ago
$ALNY recent news/filings

bullish 105.97
bull flag breakout

## source: finance.yahoo.com

Thu, 03 Dec 2015 15:40:12 GMT ~ ?Here’s why data this weekend from Alnylam's blood disease drugs could be a big deal


read full: http://www.bizjournals.com/boston/blog/bioflash/2015/12/here-s-why-data-this-weekend-from-alnylams-blood.html?ana=yahoo
*********************************************************

Wed, 02 Dec 2015 21:30:15 GMT ~ Alnylam to Webcast R&D Day

[at noodls] - 12.02.2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day live on the ...

read full: http://www.noodls.com/view/C3422FC54BF2109F56776782E42C2ABAE12B742E
*********************************************************

Wed, 02 Dec 2015 21:00:00 GMT ~ Alnylam to Webcast R&D Day

[Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day live on the Investors section of the company’s website, www.alnylam.com the morning of December 10, 2015.

read full: http://finance.yahoo.com/news/alnylam-webcast-r-d-day-210000301.html
*********************************************************

Mon, 30 Nov 2015 18:13:08 GMT ~ Leerink Highlights Biotechs Poised To Benefit From ASH Conference


read full: http://finance.yahoo.com/news/leerink-highlights-biotechs-poised-benefit-181308538.html
*********************************************************

Mon, 23 Nov 2015 21:30:15 GMT ~ Alnylam to Webcast Presentations at Upcoming December Investor Conferences

[at noodls] - 11.23.2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the ...

read full: http://www.noodls.com/view/3E8068B570838DB6E6DF42C8CFA943401A6F040C
*********************************************************

$ALNY charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ALNY company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ALNY/company-info
Ticker: $ALNY
OTC Market Place: Not Available
CIK code: 0001178670
Company name: Alnylam Pharmaceuticals, Inc.
Company website: http://www.alnylam.com
Incorporated In: DE, USA

$ALNY share structure

## source: otcmarkets.com

Market Value: $8,779,466,602 a/o Dec 02, 2015
Shares Outstanding: 84,735,707 a/o Oct 30, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.0001

$ALNY extra dd links

Company name: Alnylam Pharmaceuticals, Inc.
Company website: http://www.alnylam.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ALNY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ALNY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ALNY+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ALNY/news - http://finance.yahoo.com/q/h?s=ALNY+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ALNY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ALNY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ALNY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ALNY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Alnylam+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Alnylam+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Alnylam+Pharmaceuticals%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.alnylam.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.alnylam.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.alnylam.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ALNY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001178670&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ALNY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ALNY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ALNY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ALNY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ALNY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ALNY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ALNY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ALNY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ALNY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ALNY+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ALNY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ALNY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ALNY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ALNY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ALNY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ALNY/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ALNY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ALNY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ALNY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ALNY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ALNY



$ALNY DD Notes ~ http://www.ddnotesmaker.com/ALNY
👍️0
DewDiligence DewDiligence 9 years ago
The bear case for ALN-PCSsc: #msg-118426765.
👍️0
jrf30 jrf30 9 years ago
It was pretty solid about $40 higher than it is today, and that was only a few months ago.

So yes, i think it could go up again to a double. Not saying it WILL, but it surely could.
👍️0
tyhub tyhub 9 years ago
Does anyone BELEIVE that this stock has a chance to double in a year according to the Lightning Trend Setter's Marc Lichtenfeld??

He's even betting his check on it!!

There's always some Joker trying to rip us off!!

-Ty
👍️0

Your Recent History

Delayed Upgrade Clock